MC

488

-2.87%↓

SANES

7.21

-1.82%↓

ALV

345.9

-0.63%↓

BNP

76.34

-1.96%↓

BBVA

12.96

-3.18%↓

MC

488

-2.87%↓

SANES

7.21

-1.82%↓

ALV

345.9

-0.63%↓

BNP

76.34

-1.96%↓

BBVA

12.96

-3.18%↓

MC

488

-2.87%↓

SANES

7.21

-1.82%↓

ALV

345.9

-0.63%↓

BNP

76.34

-1.96%↓

BBVA

12.96

-3.18%↓

MC

488

-2.87%↓

SANES

7.21

-1.82%↓

ALV

345.9

-0.63%↓

BNP

76.34

-1.96%↓

BBVA

12.96

-3.18%↓

MC

488

-2.87%↓

SANES

7.21

-1.82%↓

ALV

345.9

-0.63%↓

BNP

76.34

-1.96%↓

BBVA

12.96

-3.18%↓

Search

AB Science SA

Suletud

1.374 -1.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.302

Max

1.374

Põhinäitajad

By Trading Economics

Sissetulek

-3.4M

Müük

512K

Kasumimarginaal

-656.641

Töötajad

28

EBITDA

-1.9M

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. sept 2025

Turustatistika

By TradingEconomics

Turukapital

92M

Eelmine avamishind

2.66

Eelmine sulgemishind

1.374

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

AB Science SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. juuli 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FCC Approves U.S. Cellular Sale to T-Mobile

11. juuli 2025, 17:28 UTC

Suurimad hinnamuutused turgudel

SharpLink Gaming Gains on Ethereum Purchase

11. juuli 2025, 16:57 UTC

Tulu

BASF Cuts Outlook on Global Economy Uncertainty

11. juuli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. juuli 2025, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. juuli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. juuli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. juuli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. juuli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. juuli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. juuli 2025, 16:42 UTC

Tulu

BASF Cuts Outlook on Global Economic Uncertainty

11. juuli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. juuli 2025, 16:05 UTC

Tulu

BASF Will Publish Half-Year Results on July 30

11. juuli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. juuli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. juuli 2025, 16:03 UTC

Tulu

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. juuli 2025, 16:02 UTC

Tulu

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. juuli 2025, 16:01 UTC

Tulu

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. juuli 2025, 16:00 UTC

Tulu

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. juuli 2025, 15:59 UTC

Tulu

BASF Cuts 2025 Earnings View

11. juuli 2025, 15:58 UTC

Tulu

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. juuli 2025, 15:57 UTC

Tulu

BASF 2Q EBIT Before Special Items EUR810M

11. juuli 2025, 15:54 UTC

Tulu

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. juuli 2025, 15:54 UTC

Tulu

BASF 2Q Sales Fell 2.1% on Year

11. juuli 2025, 15:53 UTC

Tulu

BASF 2Q Sales EUR15.77B

11. juuli 2025, 15:52 UTC

Tulu

BASF: This Was in Line With Consensus Estimates

11. juuli 2025, 15:52 UTC

Tulu

BASF 2Q Ebitda Before Special Items EUR1.77B

11. juuli 2025, 15:49 UTC

Tulu

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. juuli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Võrdlus sarnastega

Hinnamuutus

AB Science SA Prognoos

Tehniline skoor

By Trading Central

1.426 / 1.448Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.